[Intralesional Pingyangmycin therapy for 51 infantile patients with parotid gland hemangiomas].
OBJECTIVE
To investigate the indication and outcome of intralesional Pingyangmycin (PYM) therapy for parotid gland hemangiomas in early childhood.


METHODS
51 infantile patients with hemangiomas in the parotid gland were studied retrospectively, which had been treated in the clinic of West China Hospital of Stomatology, Sichuan University during the 15-year period from May 1990 to May 2005. In this study, 21 were male, 30 were female, and the ratio of male to female was 1:1.43. The age of the children ranged from 6 months to 4 years, with an average age of 10 months. 38 were deep-seated hemangiomas, and 13 were mixed hemangiomas. 27 were in the right parotid gland and 24 in the left, no bilateral case. All the patients underwent intralesional injection of a solution of 8 mg PYM in 8 mL normal saline mixed with 5 mg dexamethasone. The total dose of PYM ranged from 20mg to 35 mg, which was administered 0.5 or 1 mg per injection. SPSS10.0 software package was used to compare the treatment efficacy between the patients with hemangioma <4 cm in diameter and >or=4 cm in diameter.


RESULTS
Hemangiomas of 42 cases (82.35%) showed complete resolution with good appearance, 8 cases (15.69%) were partly regressed, and 1 case (1.96%) had no obvious size change. No serious side effects were seen, such as pulmonary fibrosis and growth inhibition. No significant correlation was found between treatment efficacy and tumor size.


CONCLUSIONS
Intralesional PYM therapy maybe is a selective primary therapy option for parotid gland hemangioma, and ultrasonography should be useful for diagnosis and treatment of this lesion.
Wang
Li-Li
LL
Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Gao
Qing-Hong
QH
Liu
Kun
K
Wang
Xiao-Yi
XY
Wang
Chang-Mei
CM
Wen
Yu-Ming
YM
D001761:Bleomycin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002675:Child, Preschool; D002681:China; D005260:Female; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D008297:Male; D010306:Parotid Gland; D010307:Parotid Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
D001761:Bleomycin; C025703:bleomycetin